|
EANM Congress 2010, Vienna |
|
Quarta, 17 Junho 2009 11:10 |
|
There are no translations available.
The European Association of Nuclear Medicine invites to the 23rd annual EANM Congress, 2010 at the Austria Center Vienna.
The EANM 2010 is a scientific highlight at which the best in "European Nuclear Medicine" is presented.
piCHEM will exhibit in Hall X booth #61b.
For further information see http://eanm10.eanm.org/index.php! |
|
|
CPhI Worldwide 2010, Paris |
|
Quarta, 17 Junho 2009 11:10 |
|
There are no translations available.
piCHEM will exhibit from 5 to 7 Octobre 2010 at the CPhI/ICSE Worldwide, Paris.
CPhI is the leading exhibition on pharmaceutical ingredients and allied industries.
Each year the exhibition grows larger with exhibitors and visitors conducting
significant levels of business at CPhI.
You are welcome to visit us at our booth #4G32!
|
|
"RedPaw" Pesquisa de câncer em animais |
|
Quarta, 09 Janeiro 2008 09:21 |
|
piCHEM supports the organization „RedPaw“ Cancer research for animals, which is a cooperation between the Medical University Vienna and the University of Veterinary Medicine Vienna. The organization’s mission is the exchange, joint investigation and development of new therapeutic strategies that will improve the quality of life of both humans and animals with cancer.
Please also check: www.rotepfote.at
|
|
Quinta, 12 Julho 2007 09:13 |
|
Due to a growing demand for Hynic-TOC for clincal applications, we have decided to produce a batch of Hynic-TOC in GMP-grade quality.
As the shelf-life of this peptide is rather short (approx. 12 month) only a small batch is planned. The release of the final product by our quality unit and first shipment is expected by the end of September 2007. Due to the small availability of this GMP peptide, the purchase will be performed on a first come-first served basis.
|
|
Equipe européia de liderança austríaca desenvolve vacina de Alzheimer |
|
Terça, 12 Dezembro 2006 12:13 |
A recently approved project of the sixth EU Framework Programme MimoVax is focussing on a new target for an Alzheimer's vaccine. The project, coordinated by the Austrian company Affiris GmbH, centres on the use of immune reactions to combat previously overlooked forms of the beta-amyloid that cause Alzheimer's disease. It is being run by seven partner organisations from three countries and has received an exceptionally positive response from Brussels as well as Euro 2.4 million in financial support.
|
|
more...
|
|
|
<< Início < Anterior 1 2 Seguinte > Final >>
|
|
Página 2 de 2 |
